News
Qu Biologics Closes USD$12M Equity Financing
Burnaby, British Columbia – March 21, 2022 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three […]
READ MORE >Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
Vancouver, British Columbia – July 13, 2021 – Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that data from Qu’s RESTORE clinical trial was presented at the 16th Congress of the European Crohn’s and Colitis […]
READ MORE >Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment
Vancouver, British Columbia – June 23, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and additional research and development funding of up to $1,971,195 funding from the […]
READ MORE >Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
Vancouver, British Columbia – June 9, 2021 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the data from QBECO-CD-02, Qu’s Phase 2 study of QBECO SSI treatment for Crohn’s disease, was selected for […]
READ MORE >Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis
Vancouver, British Columbia – May 12, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, recently expanded its patent portfolio to include the perioperative use of Qu’s SSIs to overcome immune dysfunction in patients undergoing cancer surgery. […]
READ MORE >Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
Vancouver, British Columbia – January 4, 2021 – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to report positive signs of clinical, endoscopic and histologic response in subjects participating in Stage 1 of their Phase 2 […]
READ MORE >Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
VANCOUVER, British Columbia, Dec-18-2020 (GLOBE NEWSWIRE) — Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research […]
READ MORE >Qu Biologics Completes $8M Financing
Vancouver, British Columbia – Dec-9-2020 (Global Newswire) – Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversubscribed $8 million financing. With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase […]
READ MORE >Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors
VANCOUVER, British Columbia — Aug-24-2020 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO of Terramera and agtech industry pioneer, has joined Qu Biologics’ Board of Directors. Karn Manhas, […]
READ MORE >Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
Vancouver, British Columbia – August-18-2020 (GlobalNews Wire) – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. […]
READ MORE >